DSP-2342

DSP-2342 is a novel, highly-selective bispecific small molecule designed as a dual antagonist of the serotonin 5-HT2A and 5-HT7 receptors. It was discovered by Sumitomo Pharma in collaboration with Exscientia using artificial intelligence-driven drug discovery technologies. The compound is being developed for broad potential use in psychiatric diseases, with anticipated antipsychotic effects that may include efficacy against psychosis, anxiety, and depression. Its high selectivity for both 5-HT2A and 5-HT7 receptors is expected to confer improved safety and tolerability profiles compared to less selective agents. DSP-2342 is administered orally and is currently in Phase 1 clinical development in the United States[1][2][4][6].